Inovio Pharmaceuticals Inc (NASDAQ:INO) CFO Sells $927,500.00 in Stock

Inovio Pharmaceuticals Inc (NASDAQ:INO) CFO Peter Kies sold 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $26.50, for a total value of $927,500.00. Following the sale, the chief financial officer now owns 119,290 shares of the company’s stock, valued at $3,161,185. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Inovio Pharmaceuticals stock opened at $21.45 on Monday. Inovio Pharmaceuticals Inc has a 52 week low of $1.91 and a 52 week high of $33.79. The business’s fifty day simple moving average is $16.28 and its 200-day simple moving average is $8.79. The firm has a market cap of $3.39 billion, a PE ratio of -18.03 and a beta of 1.47. The company has a quick ratio of 8.53, a current ratio of 8.53 and a debt-to-equity ratio of 0.51.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.04). Inovio Pharmaceuticals had a negative net margin of 4,700.42% and a negative return on equity of 166.85%. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the company earned ($0.30) EPS. As a group, equities analysts expect that Inovio Pharmaceuticals Inc will post -0.77 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its stake in Inovio Pharmaceuticals by 13.0% during the 1st quarter. BlackRock Inc. now owns 8,627,087 shares of the biopharmaceutical company’s stock worth $64,186,000 after acquiring an additional 992,487 shares in the last quarter. VR Adviser LLC acquired a new position in Inovio Pharmaceuticals during the 1st quarter worth about $21,576,000. State Street Corp increased its holdings in Inovio Pharmaceuticals by 9.5% during the 1st quarter. State Street Corp now owns 1,735,565 shares of the biopharmaceutical company’s stock worth $12,913,000 after purchasing an additional 150,421 shares during the period. Geode Capital Management LLC increased its holdings in Inovio Pharmaceuticals by 24.7% during the 1st quarter. Geode Capital Management LLC now owns 1,684,463 shares of the biopharmaceutical company’s stock worth $12,532,000 after purchasing an additional 333,382 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Inovio Pharmaceuticals during the 4th quarter worth about $3,061,000. 27.82% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently commented on the company. Royal Bank of Canada cut Inovio Pharmaceuticals to a “hold” rating in a research report on Monday, April 6th. Benchmark reiterated a “buy” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, June 30th. BidaskClub upgraded Inovio Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Cantor Fitzgerald boosted their price objective on Inovio Pharmaceuticals from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Finally, Maxim Group lowered Inovio Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 price objective on the stock. in a research note on Wednesday, July 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $13.33.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Recommended Story: How are the companies in the S&P 500 selected?

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with's FREE daily email newsletter.